[Efficacy of trastuzumab-containing regimens in patients with unresectable advanced or recurrent gastric cancer].

Abstract

In the present study, we aimed to evaluate the efficacy and safety of trastuzumab-containing regimens in patients with unresectable advanced or recurrent gastric cancer( AGC). We retrospectively analyzed 142 patients with AGC who received systemic chemotherapy, including 10 patients treated with trastuzumab-containing regimens. Among the 72 patients, 12 (16.7)% were human epidermal growth factor receptor 2 (HER2)-positive; the HER2-positive rate was significantly greater in patients with intestinal-type than diffuse-type histology( 29.0 vs 7.3%; p=0.014). The median overall survival of patients treated with trastuzumab was significantly longer than that of patients treated without trastuzumab( 22.9 vs 11.6 months; p =0.014). Seven patients continued receiving trastuzumab therapy after disease progression, and 6 patients were treated with trastuzumab after initial chemotherapy. The objective response rate of trastuzumab-containing regimens was 40%. The frequency of hematological and non-hematological toxicities was feasible. The administration of trastuzumab therapy after disease progression may contribute to improved treatment outcomes. However, further investigations, including prospective randomized controlled trials, are needed to verify this finding.

• Authors: Tsutomu Namikawa, Eri Munekage, Mai Shiga, Hiroyuki Kitagawa, Ken Dabanaka, Ken Okamoto, Michiya Kobayashi, Kazuhiro Hanazaki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 40 Issue 12 Pg. 2250-2 (Nov 2013) ISSN: 0385-0684 [Print] Japan
• PMID: 24394075 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab

Topics

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Receptor, ErbB-2 (analysis)
• Recurrence
• Retrospective Studies
• Stomach Neoplasms (chemistry, drug therapy, pathology)
• Trastuzumab
• Treatment Outcome